The most recent short interest data has been released for the 09/29/2017 settlement date, which shows a 2,063,420 share decrease in total short interest for Nymox Pharmaceutical Corp (NYMX - Get Report), to 1,179,164, a decrease of 63.64% since 09/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days (at the average volume) it would take to close out all of the open short positions if every share traded represented a short position being closed. Average daily volume for NYMX at the 09/29/2017 settlement decreased to 85,710, as compared to 139,088 at the 09/15/2017 report. That brought "days to cover" down to 13.76, a 40.99% decrease from the 23.31 days to cover calculated at the previous short interest data release.The below chart shows the historical "days to cover" for NYMX at previous short interest release dates: A decreased "days to cover" value could indicate that short sellers are no longer expecting the same decline in stock price they once were, or it could also indicate a long bet elsewhere was closed where NYMX had been shorted as a hedge. The chart below shows the one year performance of NYMX shares, versus its 200 day moving average. Looking at this chart, NYMX's low point in its 52 week range is $2.67 per share, with $5.10 as the 52 week high point — that compares with a last trade of $4.03.
More from Stocks
Brexit: UK Prime Minister Boris Johnson Loses Key Vote to Avoid EU Exit Delay
U.K. lawmakers voted Saturday to delay approval of Prime Minister Boris Johnson's Brexit deal, setting up a potentially unprecedented clash between the country's ruling party and the Supreme Court.
Zuckerberg Set to Defend Libra on Capitol Hill Next Week. Here's What to Expect
While the hearing is focused on Facebook's Libra project, the congressional grilling could also extend to Facebook's acquisitions, antitrust concerns and posture on free speech.